Clinical trialNCT04329728RecruitingPhase 1/PHASE2Interventional

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

SponsorAVM Biotechnology IncEnrollment144Lymphoid Malignancies

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel Kerr, MD
ASCLEPES Research Centers
Principal Investigator
clinicaltrials.gov ↗
Don Stevens, MD
Norton Cancer Institute
Principal Investigator
clinicaltrials.gov ↗
Elizabeth Budde, MD
City of Hope Medical Center
Principal Investigator
clinicaltrials.gov ↗
Gary Schiller, MD
University of California, Los Angeles
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Lasika Seneviratne, MD
Los Angeles Cancer Network
Principal Investigator
clinicaltrials.gov ↗
Nashat Gabrail, MD
Gabrail Cancer Center Research
Principal Investigator
clinicaltrials.gov ↗
Pamela Miel, MD
Innovative Clinical Research Institute
Principal Investigator
clinicaltrials.gov ↗
Paul Rubinstein, MD
University of Illinois at Chicago
Principal Investigator
clinicaltrials.gov ↗
Salil Goorha, MD
Memphis Baptist Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Stefano Tarantolo, MD
Nebraska Cancer Specialists
Principal Investigator
clinicaltrials.gov ↗
Tamra Slone, MD
U Texas SouthWestern
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Elizabeth Budde
Recruiting
Los Angeles Cancer Network
Los Angeles, California, United States
Lasika Seneviratne
Recruiting
Ucla Medical Center of Hematology/oncology
Los Angeles, California, United States
Gary J Schiller
Recruiting
Innovative Clinical Research Institute
Whittier, California, United States
Recruiting
Asclepes Research Centers
Weeki Wachee, Florida, United States
Recruiting
University of Illinois at Chicago Cancer Center
Chicago, Illinois, United States
Recruiting
Norton Cancer Institute
Louisville, Kentucky, United States
Don Stevens, MD
Recruiting
Oncology Hematology West P.C. Dba Nebraska Cancer Specialists
Omaha, Nebraska, United States
Ryan Ramaekers, MDStefano Tarantolo, MD
Recruiting
Gabrail Cancer Center Research,
Canton, Ohio, United States
Recruiting
Baptist Clinical Research Institute
Memphis, Tennessee, United States
Salil Goorha
Recruiting
University of Texas(ut) Southwestern-Children'S Medical Center
Dallas, Texas, United States
Slone Tamra
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AVM0703

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Nov 2020
Primary completion: 30 Nov 2027
Completion: 1 Dec 2028
Last update posted: 15 Apr 2026
Registered enrollment: 144
Registry id: NCT04329728

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.